Metabolic Effects of Empagliflozin in Patients with Type 2 Diabetes Mellitus and Obesity

Aim: to study metabolic effects of empaglilozin in patients with type 2 diabetes and obesity. Design. Single center prospective randomized study. Materials and Methods. The study included 46 patients (10 men and 36 women) aged 37–69 years with previously diagnosed T2D and obesity. Patients were randomized into two groups by random numbers: in the main group (n = 22), empagliflozin 25 mg/day was added to metformin 2000 mg/day, the control group (n = 24) continued therapy with metformin 2000 mg/day. We looked such indicators, as anthropometric data were assessed: body weight (BW), waist circumference (WC), body mass index (BMI), glycemic control, and metabolic health markers (adiponectin, leptin) at baseline and after 6 months of therapy. Results. Although we didn’t find pronounced glycemic effect in the combined treatment group, but we showed positive dynamics of anthropometric parameters — a decrease in BW (p = 0.035), WC (p = 0.04), BMI (p = 0.005) — we found a decrease in leptin levels from 28.8 ± 11.0 to 21.0 ± 9.13 ng/ml (p = 0.035). In the main group, the level of adiponectin increased statistically significantly (p = 0.002) from 9.70 ± 2.15 to 13.0 ± 3.18 μg/ml. Conclusion. Significant non-glycemic effects of empagliflozin were obtained. Keywords: type 2 diabetes mellitus, obesity, empagliflozin.